We were told that the original term sheet was for OM but that the BP wanted to expand it to IBD as well. Now as to what is being discussed tody considering what will be partnered in the first deal, who knows? I am sure if OM suffices, that is all we partner. If it isn't, then we have to throw in IBD. That is not to say we are giving up all of Brilacidin, just those 2 indications at the most and no problem with that if we get a good enough deal.
(2)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links